Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 2:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 70 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Empagliflozin 10 mg Clear all
Recruiting Early Phase 1 Interventional

SGLT2i in Kidney Stones

NCT07055282
View directory record Official record
Conditions
Kidney Stones
Interventions
Empagliflozin (Jardiance®)
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 1, 2026, 2:27 PM EDT
Completed Phase 2 Interventional Results available

BI 10773 add-on to Metformin in Patients With Type 2 Diabetes

NCT00749190
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BI 10773, placebo, sitagliptin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 79 Years
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
19
States / cities
Chula Vista, California • Mission Viejo, California • Pasadena, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2014 · Synced Oct 1, 2026, 2:27 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

NCT05282121
View directory record Official record
Conditions
Liver Diseases, Hypertension, Portal
Interventions
Avenciguat, Empagliflozin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Pasadena, California • Rialto, California • Miami Lakes, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 1, 2026, 2:27 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus

NCT01306214
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Obesity
Interventions
Placebo, BI 10773
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
566 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
26
States / cities
Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Oct 1, 2026, 2:27 PM EDT
Recruiting Phase 4 Interventional

Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD

NCT06110130
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Empagliflozin 10 MG, Placebo
Drug
Lead sponsor
Washington D.C. Veterans Affairs Medical Center
Federal
Eligibility
19 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 1, 2026, 2:27 PM EDT
Active, not recruiting Phase 1 Interventional

Effects of Acute and Chronic Empagliflozin Heart Failure

NCT05553938
View directory record Official record
Conditions
Heart Failure
Interventions
Empagliflozin 10 mg, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 1, 2026, 2:27 PM EDT
Recruiting Phase 2 Interventional

Empagliflozin in Patients With Cirrhosis and Ascites

NCT05726032
View directory record Official record
Conditions
Cirrhosis, Liver Failure
Interventions
Empagliflozin 10 MG, Matching Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 1, 2026, 2:27 PM EDT
Not yet recruiting Phase 2 Interventional

Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's Disease

NCT07756294
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Empagliflozin, Insulin, Insulin Placebo, Empagliflozin Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 1, 2026, 2:27 PM EDT
Not yet recruiting Phase 2 Interventional

Vascular Effects of SGLT2i in Non-diabetic CKD

NCT07060417
View directory record Official record
Conditions
Non-diabetic Chronic Kidney Disease
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 1, 2026, 2:27 PM EDT
Active, not recruiting Phase 4 Interventional

Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease

NCT05671991
View directory record Official record
Conditions
End Stage Renal Disease on Dialysis
Interventions
Empagliflozin 25 mg vs Placebo, Empagliflozin 10 MG
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 1, 2026, 2:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets

NCT02106923
View directory record Official record
Conditions
Healthy
Interventions
1 tablet Empagliflozin/2 tablets Metformin XR, 10 mg Empagliflozin/1000 mg Metformin XR, 1 tablet 10 mg Empagliflozin/3 tablets Metformin XR, 2 tablets 5 mg Empagliflozin/750 Metformin XR
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 1, 2026, 2:27 PM EDT
Terminated Phase 3 Interventional

Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin

NCT03060980
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
ITCA 650 20/60 mcg/day, Empagliflozin (oral), Glimepiride (oral)
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
96
States / cities
Fountain Hills, Arizona • Glendale, Arizona • Phoenix, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Oct 1, 2026, 2:27 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease

NCT05182840
View directory record Official record
Conditions
Kidney Disease, Chronic
Interventions
BI 690517, Placebo to BI 690517, Empagliflozin, Placebo to empagliflozin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
41
States / cities
Mesa, Arizona • Phoenix, Arizona • Canyon Country, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Oct 1, 2026, 2:27 PM EDT
Completed Phase 4 Interventional Results available

Empagliflozin Impact on Hemodynamics in Patients With Heart Failure

NCT03030222
View directory record Official record
Conditions
Heart Failure
Interventions
Empagliflozin 10 mg Tab, Placebo Oral Tablet
Drug
Lead sponsor
Saint Luke's Health System
Other
Eligibility
19 Years to 119 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
10
States / cities
Los Angeles, California • Jacksonville, Florida • Evanston, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Oct 1, 2026, 2:27 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

NCT01422876
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
high dose FDC, BI 10773 high dose, high dose FDC placebo, low dose FDC placebo, high dose BI 10773 placebo, low dose FDC, BI 10773 low dose, linagliptin, linagliptin placebo, BI 10773 low dose placebo, low dose BI 10773 placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
112
States / cities
Birmingham, Alabama • Foley, Alabama • Mobile, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2015 · Synced Oct 1, 2026, 2:27 PM EDT
Recruiting Phase 2 Interventional

Safety and Efficacy of Empagliflozin in Hemodialysis

NCT05786443
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Empagliflozin 10 MG, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 1, 2026, 2:27 PM EDT
Recruiting Early Phase 1 Interventional

Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease

NCT06430684
View directory record Official record
Conditions
Chronic Kidney Diseases, Pediatric Kidney Disease
Interventions
Empagliflozin 10 MG
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
12 Years to 25 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 1, 2026, 2:27 PM EDT
Completed Phase 3 Interventional Results available

12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus

NCT01370005
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hypertension
Interventions
Placebo, BI 10773
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
825 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
35
States / cities
Huntsville, Alabama • Phoenix, Arizona • Lincoln, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Oct 1, 2026, 2:27 PM EDT
Recruiting Phase 4 Interventional

SGLT2i Therapy in Islet Transplantation (SIT)

NCT07228195
View directory record Official record
Conditions
Partial Islet Function, TPIAT, Diabetes
Interventions
Empagliflozin 25 MG Oral Tablet, Empagliflozin 10 MG Oral Tablet [Jardiance]
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 1, 2026, 2:27 PM EDT
Completed Phase 4 Interventional

Use of Empagliflozin to Treat Prediabetes

NCT05426525
View directory record Official record
Conditions
PreDiabetes, Prediabetic State, Overweight and Obesity
Interventions
Empagliflozin, Multivitamin-Placebo
Drug
Lead sponsor
Oregon State University
Other
Eligibility
18 Years to 59 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Corvallis, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 1, 2026, 2:27 PM EDT
Completed Phase 1 Interventional

Drug Interaction Study Between Dorzagliatin and Empagliflozin

NCT03790787
View directory record Official record
Conditions
Patients
Interventions
Empagliflozin, Dorzagliatin
Drug
Lead sponsor
Hua Medicine Limited
Industry
Eligibility
30 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 1, 2026, 2:27 PM EDT
Completed Phase 3 Interventional Results available

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

NCT03057951
View directory record Official record
Conditions
Heart Failure
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
5,988 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
135
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 116 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Oct 1, 2026, 2:27 PM EDT
Withdrawn Phase 3 Interventional

Empaglifozin in Early Diabetic Kidney Disease

NCT03173963
View directory record Official record
Conditions
Diabetic Kidney Disease, Diabetes Mellitus Type 2
Interventions
Empagliflozin, Placebo
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 1, 2026, 2:27 PM EDT
Recruiting Phase 2 Interventional

Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension

NCT06992440
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Empagliflozin 10 MG, Placebo
Drug
Lead sponsor
Gustavo A Heresi, MD, MS
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Baltimore, Maryland • Cleveland, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 1, 2026, 2:27 PM EDT